ESLA

$0.00

(

0.00%

)
Quote details

stock

Estrella Immunopharma Inc.

NASDAQ | ESLA

2.27

USD

$0.00

(

0.00%

)

At Close (As of Oct 23, 2025)

$69.31M

Market Cap

-

P/E Ratio

-0.24

EPS

$2.42

52 Week High

$0.63

52 Week Low

HEALTHCARE

Sector

ESLA Chart

Recent Chart
Price Action

ESLA Technicals

Tags:

ESLA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (None)
Gross Profit -
Total Revenue -
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$8.8M
Selling General And Administrative $1.4M
Research And Development $6.4M
Operating Expenses $8.8M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$40K
Income Before Tax -$8.8M
Income Tax Expense $1.7K
Interest And Debt Expense -
Net Income From Continuing Operations -
Comprehensive Income Net Of Tax -
Ebit -$8.8M
Ebitda -$8.8M
Net Income -$8.8M

Revenue & Profitability

Earnings Performance

ESLA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (None)
Total Assets $3.1M
Total Current Assets $1.6M
Cash And Cash Equivalents At Carrying Value $917K
Cash And Short Term Investments $917K
Inventory -
Current Net Receivables $289K
Total Non Current Assets $1.5M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $724K
Other Non Current Assets -
Total Liabilities $3M
Total Current Liabilities $3M
Current Accounts Payable -
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities -
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $3M
Other Non Current Liabilities -
Total Shareholder Equity $144K
Treasury Stock -
Retained Earnings -$24M
Common Stock $3.7K
Common Stock Shares Outstanding $37M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (None)
Operating Cashflow -$7.6M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $1
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $5M
Cashflow From Financing -$489K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$569K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$8.8M

yearly Income Statement (As of Dec 31, 2024)

Field Value (None)
Gross Profit -
Total Revenue -
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$8.8M
Selling General And Administrative $1.4M
Research And Development $6.4M
Operating Expenses $8.8M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$40K
Income Before Tax -$8.8M
Income Tax Expense $1.7K
Interest And Debt Expense -
Net Income From Continuing Operations -
Comprehensive Income Net Of Tax -
Ebit -$8.8M
Ebitda -$8.8M
Net Income -$8.8M

ESLA News

ESLA Profile

Estrella Immunopharma Inc. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company based in Emeryville, California, focused on pioneering T-cell therapies aimed at treating blood cancers and solid tumors. With a strong commitment to advancing innovative immunotherapy solutions, Estrella seeks to address critical unmet medical needs in oncology. The company’s cutting-edge research and development efforts position it as a key player in the evolving landscape of cancer treatment, with an emphasis on harnessing the immune system to combat malignancies.

BYND
-1.10%
$3.58
YDKG
+14.70%
$0.07
YYAI
-46.43%
$0.10
VHAI
0.00%
$0.00
SCNX
+125.72%
$1.29
CGBS
-39.47%
$0.03
BITF
-12.24%
$3.94
WTO
+10.81%
$0.07
TLRY
-2.02%
$1.45
VTYX
+82.90%
$7.06
AXDX
-61.36%
$0.03
AMD
-3.27%
$230.23
RGTI
+14.70%
$41.36
AAL
-2.10%
$12.09
NVTS
-9.48%
$13.60
NIO
+0.58%
$6.84
HPE
-0.77%
$23.09
AREB
+37.20%
$2.95
ADAP
+7.31%
$0.07
F
-1.08%
$12.29
QBTS
+19.10%
$32.50
RIVN
-2.12%
$12.92
MARA
-4.58%
$19.14
RMBL
+60.50%
$3.21
IONZ
-18.13%
$3.81
ADD
-25.47%
$0.05
DVLT
-15.41%
$2.14
GOOGL
+0.49%
$251.69
BAC
-0.81%
$51.10
SRM
+53.27%
$10.30
RBNE
+28.34%
$1.63
BURU
-6.30%
$0.33
SGBX
+40.78%
$3.21
PBR
+1.47%
$11.73
VIVK
+7.79%
$0.24
NDLS
+33.01%
$0.95
CUTR
-10.19%
$0.09
WLGS
-5.57%
$0.04
ETWO
0.00%
$3.30
ITUB
+0.56%
$7.07
AFMD
-34.94%
$0.18
BTE
+2.71%
$2.27
TNGX
-5.08%
$8.22
MU
-1.88%
$198.47
NEHC
-12.47%
$3.79
IBIO
-2.87%
$1.35
RGTZ
-25.52%
$13.92
OPI
-16.97%
$0.20
KLG
-9.05%
$13.35
QUBT
+9.34%
$16.26
AG
-0.70%
$12.66
QS
+11.68%
$15.16
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
RIG
+3.90%
$3.55
SMCI
-5.80%
$49.45
LAES
+11.20%
$6.00
INTC
+0.20%
$36.99
KDLY
-4.25%
$0.72
TSLA
-4.40%
$419.62
IONQ
+7.63%
$59.68
TSM
-1.91%
$288.88
CSCO
-0.08%
$70.66
SAND
-6.04%
$12.12
WWR
-15.84%
$1.54
SHOT
-74.37%
$0.39
NVDA
+0.20%
$180.65
SOFI
+1.59%
$27.62
TMQ
-7.19%
$5.16
ZAPP
-46.30%
$0.15
NOK
+8.19%
$6.00
PSTV
-4.84%
$0.58
CAN
+7.03%
$1.82
IVF
+17.48%
$0.63
NAYA
+17.48%
$0.63
T
-2.44%
$24.92
PTEN
+0.82%
$6.08
IBRX
-3.27%
$2.36
ELBM
+6.02%
$1.76
MRK
-0.01%
$87.61
GPUS
-3.89%
$0.37
CIFR
+2.88%
$16.57
EONR
+11.95%
$0.70
AIRE
+4.45%
$0.74
EPWK
-1.98%
$0.07
AA
-4.24%
$35.65
UUUU
+1.01%
$22.97
CRM
-2.57%
$256.64
PLUG
+2.16%
$2.98
TE
-8.25%
$4.11
BTBT
+0.55%
$3.60
CJET
-8.24%
$0.09
ONDS
+3.18%
$6.95
FL
-0.37%
$24.01
AVAH
-7.38%
$9.47
BNKK
-0.62%
$0.22
ETHE
-4.95%
$31.26
JOBY
+1.60%
$15.71
BTG
+0.83%
$5.25
VGFC
-1.90%
$0.05
BYND
-1.10%
$3.58
YDKG
+14.70%
$0.07
YYAI
-46.43%
$0.10
VHAI
0.00%
$0.00
SCNX
+125.72%
$1.29
CGBS
-39.47%
$0.03
BITF
-12.24%
$3.94
WTO
+10.81%
$0.07
TLRY
-2.02%
$1.45
VTYX
+82.90%
$7.06
AXDX
-61.36%
$0.03
AMD
-3.27%
$230.23
RGTI
+14.70%
$41.36
AAL
-2.10%
$12.09
NVTS
-9.48%
$13.60
NIO
+0.58%
$6.84
HPE
-0.77%
$23.09
AREB
+37.20%
$2.95
ADAP
+7.31%
$0.07
F
-1.08%
$12.29
QBTS
+19.10%
$32.50
RIVN
-2.12%
$12.92
MARA
-4.58%
$19.14
RMBL
+60.50%
$3.21
IONZ
-18.13%
$3.81
ADD
-25.47%
$0.05
DVLT
-15.41%
$2.14
GOOGL
+0.49%
$251.69
BAC
-0.81%
$51.10
SRM
+53.27%
$10.30
RBNE
+28.34%
$1.63
BURU
-6.30%
$0.33
SGBX
+40.78%
$3.21
PBR
+1.47%
$11.73
VIVK
+7.79%
$0.24
NDLS
+33.01%
$0.95
CUTR
-10.19%
$0.09
WLGS
-5.57%
$0.04
ETWO
0.00%
$3.30
ITUB
+0.56%
$7.07
AFMD
-34.94%
$0.18
BTE
+2.71%
$2.27
TNGX
-5.08%
$8.22
MU
-1.88%
$198.47
NEHC
-12.47%
$3.79
IBIO
-2.87%
$1.35
RGTZ
-25.52%
$13.92
OPI
-16.97%
$0.20
KLG
-9.05%
$13.35
QUBT
+9.34%
$16.26
AG
-0.70%
$12.66
QS
+11.68%
$15.16
GRYP
-10.38%
$1.38
MODV
-25.22%
$0.43
RIG
+3.90%
$3.55
SMCI
-5.80%
$49.45
LAES
+11.20%
$6.00
INTC
+0.20%
$36.99
KDLY
-4.25%
$0.72
TSLA
-4.40%
$419.62
IONQ
+7.63%
$59.68
TSM
-1.91%
$288.88
CSCO
-0.08%
$70.66
SAND
-6.04%
$12.12
WWR
-15.84%
$1.54
SHOT
-74.37%
$0.39
NVDA
+0.20%
$180.65
SOFI
+1.59%
$27.62
TMQ
-7.19%
$5.16
ZAPP
-46.30%
$0.15
NOK
+8.19%
$6.00
PSTV
-4.84%
$0.58
CAN
+7.03%
$1.82
IVF
+17.48%
$0.63
NAYA
+17.48%
$0.63
T
-2.44%
$24.92
PTEN
+0.82%
$6.08
IBRX
-3.27%
$2.36
ELBM
+6.02%
$1.76
MRK
-0.01%
$87.61
GPUS
-3.89%
$0.37
CIFR
+2.88%
$16.57
EONR
+11.95%
$0.70
AIRE
+4.45%
$0.74
EPWK
-1.98%
$0.07
AA
-4.24%
$35.65
UUUU
+1.01%
$22.97
CRM
-2.57%
$256.64
PLUG
+2.16%
$2.98
TE
-8.25%
$4.11
BTBT
+0.55%
$3.60
CJET
-8.24%
$0.09
ONDS
+3.18%
$6.95
FL
-0.37%
$24.01
AVAH
-7.38%
$9.47
BNKK
-0.62%
$0.22
ETHE
-4.95%
$31.26
JOBY
+1.60%
$15.71
BTG
+0.83%
$5.25
VGFC
-1.90%
$0.05

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.